Table 1.
Patient Characteristic | Total |
Adjudication Status |
||||
---|---|---|---|---|---|---|
Paid or Reversed With Follow-Up |
Abandoned |
|||||
No. | % | No. | % | No. | % | |
Total patients | 10,508 | 100.0 | 9,455 | 90.0 | 1,053 | 10.0 |
Age, years* | ||||||
0-40 | 302 | 2.9 | 272 | 90.1 | 30 | 9.9 |
41-65 | 5,109 | 48.6 | 4,672 | 91.5 | 437 | 8.6 |
65-80 | 3,837 | 36.5 | 3,419 | 89.1 | 418 | 10.9 |
> 81 | 1,260 | 12.0 | 1,092 | 86.7 | 168 | 13.3 |
Sex | ||||||
Female | 5,548 | 52.8 | 5,009 | 90.3 | 539 | 9.7 |
Male | 4,960 | 47.2 | 4,446 | 89.6 | 514 | 10.4 |
Annual household income* | ||||||
< $40,000 | 2,721 | 25.9 | 2,410 | 88.6 | 311 | 11.4 |
$40,000-$75,000 | 4,038 | 38.4 | 3,626 | 89.8 | 412 | 10.2 |
> $75,000 | 3,749 | 35.7 | 3,419 | 91.2 | 330 | 8.8 |
Geographic region | ||||||
Midwest | 2,355 | 22.4 | 2,105 | 89.4 | 250 | 10.6 |
Northeast | 2,764 | 26.3 | 2,479 | 89.7 | 285 | 10.3 |
South | 3,692 | 35.1 | 3,343 | 90.6 | 349 | 9.5 |
West | 1,697 | 16.1 | 1,528 | 90.0 | 169 | 10.0 |
Patient cost-sharing amount* | ||||||
$0-$100 | 7,638 | 72.7 | 7,147 | 93.6 | 491 | 6.4 |
$101-$150 | 271 | 2.6 | 242 | 89.3 | 29 | 10.7 |
$151-$200 | 258 | 2.5 | 234 | 90.7 | 24 | 9.3 |
$201-$250 | 123 | 1.2 | 108 | 87.8 | 15 | 12.2 |
$251-$350 | 291 | 2.8 | 256 | 88.0 | 35 | 12.0 |
$351-$500 | 200 | 1.9 | 168 | 84.0 | 32 | 16.0 |
> $500 | 1,727 | 16.4 | 1,300 | 75.3 | 427 | 24.7 |
Insurance type* | ||||||
Medicare | 1,737 | 16.5 | 1,467 | 84.5 | 270 | 15.5 |
Commercial | 8,771 | 83.5 | 7,988 | 91.1 | 783 | 8.9 |
Prescription activity, No. of claims* | ||||||
0 | 3,049 | 29.0 | 2,775 | 91.0 | 274 | 9.0 |
1 | 1,318 | 12.5 | 1,207 | 91.6 | 111 | 8.4 |
2-3 | 2,168 | 20.6 | 1,947 | 89.8 | 221 | 10.2 |
4-5 | 1,550 | 14.8 | 1,383 | 89.2 | 167 | 10.8 |
> 5 | 2,423 | 23.1 | 2,143 | 88.4 | 280 | 11.6 |
Study drug* | ||||||
Capecitabine | 3,758 | 35.8 | 3,527 | 93.9 | 231 | 6.2 |
Imatinib | 1,380 | 13.1 | 1,194 | 86.5 | 186 | 13.5 |
Sorafenib | 460 | 4.4 | 335 | 72.8 | 125 | 27.2 |
Lenalidomide | 1,038 | 9.9 | 960 | 92.5 | 78 | 7.5 |
Sunitinib | 569 | 5.4 | 501 | 88.1 | 68 | 12.0 |
Erlotinib | 2,022 | 19.2 | 1,763 | 87.2 | 259 | 12.8 |
Temozolomide | 1,060 | 10.1 | 982 | 92.6 | 78 | 7.4 |
Lapatinib | 221 | 2.1 | 193 | 87.3 | 28 | 12.7 |
χ2; P < .05.